151 related articles for article (PubMed ID: 35243381)
41. Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods.
Lloyd IE; Zhou W; Witt BL; Chadwick BE
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):107-113. PubMed ID: 29084060
[TBL] [Abstract][Full Text] [Related]
42. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
Sánchez-Magraner L; Gumuzio J; Miles J; Quimi N; Martínez Del Prado P; Abad-Villar MT; Pikabea F; Ortega L; Etxezarraga C; Martín-Algarra S; Lozano MD; Saiz-Camin M; Egurrola-Izquierdo M; Barredo-Santamaría I; Saiz-López A; Gomez-Mediavilla J; Segues-Merino N; Juaristi-Abaunz MA; Urruticoechea A; Geraedts EJ; van Elst K; Claessens NJM; Italiano A; Applebee CJ; Del Castillo S; Evans C; Aguirre F; Parker PJ; Calleja V
J Clin Oncol; 2023 May; 41(14):2561-2570. PubMed ID: 36821809
[TBL] [Abstract][Full Text] [Related]
43. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
[TBL] [Abstract][Full Text] [Related]
44. Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.
Ligero M; Serna G; El Nahhas OSM; Sansano I; Mauchanski S; Viaplana C; Calderaro J; Toledo RA; Dienstmann R; Vanguri RS; Sauter JL; Sanchez-Vega F; Shah SP; Ramón Y Cajal S; Garralda E; Nuciforo P; Perez-Lopez R; Kather JN
Cancer Res Commun; 2024 Jan; 4(1):92-102. PubMed ID: 38126740
[TBL] [Abstract][Full Text] [Related]
45. Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology.
Lin YY; Wang LC; Hsieh YH; Hung YL; Chen YA; Lin YC; Lin YY; Chou TY
J Transl Med; 2022 Mar; 20(1):131. PubMed ID: 35296339
[TBL] [Abstract][Full Text] [Related]
46. Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy.
Hao J; Wang J; Dong Y; Yang J; Wang Z; Zhao X; Zeng T; Zhao X; Liang H; Li J
Anal Chem; 2023 May; 95(17):6854-6862. PubMed ID: 37027485
[TBL] [Abstract][Full Text] [Related]
47. PD-L1 and beyond: Immuno-oncology in cytopathology.
Iaccarino A; Salatiello M; Migliatico I; De Luca C; Gragnano G; Russo M; Bellevicine C; Malapelle U; Troncone G; Vigliar E
Cytopathology; 2021 Sep; 32(5):596-603. PubMed ID: 33955097
[TBL] [Abstract][Full Text] [Related]
48. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images.
Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW
Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695
[TBL] [Abstract][Full Text] [Related]
49. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW
J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534
[TBL] [Abstract][Full Text] [Related]
50. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Jain D; Sukumar S; Mohan A; Iyer VK
Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855
[TBL] [Abstract][Full Text] [Related]
51. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
52. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
53. PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Sunshine JC; Nguyen PL; Kaunitz GJ; Cottrell TR; Berry S; Esandrio J; Xu H; Ogurtsova A; Bleich KB; Cornish TC; Lipson EJ; Anders RA; Taube JM
Clin Cancer Res; 2017 Aug; 23(16):4938-4944. PubMed ID: 28428193
[No Abstract] [Full Text] [Related]
54. PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers.
Lambros L; Quintin-Roué I; Bourhis A; Remoué A; Le Flahec G; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):437-443. PubMed ID: 31498156
[TBL] [Abstract][Full Text] [Related]
55. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Liu D; Wang S; Bindeman W
J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
[TBL] [Abstract][Full Text] [Related]
56. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
Kim B; Sun R; Oh W; Kim AMJ; Schwarz JR; Lim SO
Mol Carcinog; 2020 Jul; 59(7):691-700. PubMed ID: 32115801
[TBL] [Abstract][Full Text] [Related]
57. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
Ghiringhelli F; Bibeau F; Greillier L; Fumet JD; Ilie A; Monville F; Laugé C; Catteau A; Boquet I; Majdi A; Morgand E; Oulkhouir Y; Brandone N; Adam J; Sbarrato T; Kassambara A; Fieschi J; Garcia S; Lepage AL; Tomasini P; Galon J
EBioMedicine; 2023 Jun; 92():104633. PubMed ID: 37244159
[TBL] [Abstract][Full Text] [Related]
58. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
59. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical Analysis of Programmed Death-Ligand 1 Expression in Equine Sarcoids.
Benvegnen J; De Breuyn B; Gerber V; Rottenberg S; Koch C
J Equine Vet Sci; 2021 Feb; 97():103338. PubMed ID: 33478763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
